332 related articles for article (PubMed ID: 25897811)
1. Therapeutics and vaccines against chikungunya virus.
Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
[TBL] [Abstract][Full Text] [Related]
2. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
3. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
4. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
Clayton AM
J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
[TBL] [Abstract][Full Text] [Related]
6. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.
Eldi P; Cooper TH; Liu L; Prow NA; Diener KR; Howley PM; Suhrbier A; Hayball JD
Mol Ther; 2017 Oct; 25(10):2332-2344. PubMed ID: 28720468
[TBL] [Abstract][Full Text] [Related]
7. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
[TBL] [Abstract][Full Text] [Related]
8. Vaccine and Therapeutic Options To Control Chikungunya Virus.
Powers AM
Clin Microbiol Rev; 2018 Jan; 31(1):. PubMed ID: 29237708
[TBL] [Abstract][Full Text] [Related]
9. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
Bhakat S; Karubiu W; Jayaprakash V; Soliman ME
Eur J Med Chem; 2014 Nov; 87():677-702. PubMed ID: 25305334
[TBL] [Abstract][Full Text] [Related]
10. Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.
Yang S; Fink D; Hulse A; Pratt RD
Vaccine; 2017 Sep; 35(37):4851-4858. PubMed ID: 28760614
[TBL] [Abstract][Full Text] [Related]
11. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
12. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
13. Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.
Salazar-González JA; Angulo C; Rosales-Mendoza S
Vaccine; 2015 Jul; 33(31):3650-8. PubMed ID: 26073010
[TBL] [Abstract][Full Text] [Related]
14. Do we need a vaccine against chikungunya?
Rezza G
Pathog Glob Health; 2015 Jun; 109(4):170-3. PubMed ID: 25971340
[TBL] [Abstract][Full Text] [Related]
15. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment.
Hasan MA; Khan MA; Datta A; Mazumder MH; Hossain MU
Mol Immunol; 2015 May; 65(1):189-204. PubMed ID: 25682054
[TBL] [Abstract][Full Text] [Related]
17. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Roques P; Ljungberg K; Kümmerer BM; Gosse L; Dereuddre-Bosquet N; Tchitchek N; Hallengärd D; García-Arriaza J; Meinke A; Esteban M; Merits A; Le Grand R; Liljeström P
JCI Insight; 2017 Mar; 2(6):e83527. PubMed ID: 28352649
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of a peptide-fusion protein (Latarcin-PAP1-Thanatin) against chikungunya virus.
Rothan HA; Bahrani H; Shankar EM; Rahman NA; Yusof R
Antiviral Res; 2014 Aug; 108():173-80. PubMed ID: 24929084
[TBL] [Abstract][Full Text] [Related]
19. Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.
Adam A; Luo H; Osman SR; Wang B; Roundy CM; Auguste AJ; Plante KS; Peng BH; Thangamani S; Frolova EI; Frolov I; Weaver SC; Wang T
Emerg Microbes Infect; 2021 Dec; 10(1):305-316. PubMed ID: 33539255
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]